Developing Real-World Patient Pathways in Acute Pulmonary Embolism

This symposium took place on 29th August 2016 as a part of the European Society of Cardiology (ESC) Congress in Rome, Italy

Chairperson: Stavros V. Konstantinides1
Speakers: Rodney Hughes,2 David Jiminéz,3 John Eikelboom4

1. Center for Thrombosis and Hemostasis, University of Mainz, Mainz, Germany
2. Academic Directorate of Respiratory Medicine, University of Sheffield, Sheffield, UK
3. Respiratory Department, Ramón y Cajal Hospital, IRYCIS, Madrid, Spain
4. Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Disclosure: Prof Konstantinides has received fees for consultancy and/or lectures from Bayer HealthCare, Boehringer Ingelheim, Daiichi Sankyo, Pfizer/Bristol-Myers Squibb, GSK, and Actelion. His institution has received research support from Bayer HealthCare, Boehringer Ingelheim, and Actelion. Dr Hughes has received speaker fees from Actelion, AstraZeneca, Bayer, GSK, Novartis, Pfizer, and United Therapeutics, and participated in advisory boards for Bayer, Novartis, GSK, Sanofi, and Actelion. He has also received support for congress attendance from Actelion, AstraZeneca, Bayer, Boehringer Ingelheim, and GSK, and was formerly a medical advisor for Bayer. Prof Jiménez has received research support from Daiichi Sankyo and Sanofi, and consultancy fees/honoraria from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi for whom he has also participated in advisory boards. He has also participated in speaker bureaus for Bayer, Bristol-Myers Squibb, and Sanofi. Dr Eikelboom has received honoraria for consultancy and scientific advisory board participation for Bayer, Johnson & Johnson, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, and Portola.
Acknowledgements: Writing assistance was provided by Sandy Agnew of ApotheCom.
Support: The symposium and the publication of this article was funded by Bayer Pharma AG. The views and opinions expressed are those of the authors and not necessarily Bayer Pharma AG.
Citation: EMJ Cardiol. 2016;4[1]:42-49.

Meeting Summary

This case-based satellite symposium chaired by Prof Konstantinides addressed important and topical aspects of the management of acute pulmonary embolism (PE) with a focus on effective management in a real-world setting. The objectives of the symposium were to provide information and expert guidance on the effective management of a patient with PE from diagnosis and assessment of severity, through to the practical use of non-vitamin K antagonist non-oral anticoagulants (NOACs) and the management of challenging cases found in routine clinical practice. Following Prof Konstantinides’ introduction, Dr Hughes presented a low-risk PE case and discussed assessment of the severity of PE, the optimisation of hospital care, and the importance of patient discharge protocols and clear integrated management pathways. Dr Jiménez went on to illustrate the use of risk assessment and non-vitamin K antagonist (VKA) therapies through consideration of an intermediate high risk PE case with comorbidities. Finally, Dr Eikelboom presented an unprovoked PE case and discussed the key question of ‘how long is long enough’, emphasising the importance of adequate anticoagulation, both acutely and in prevention of recurrence, and the potential benefits of NOACs. In a final Question and Answer Hub session, the audience were able to participate in a lively case-based discussion.

Download (PDF, 117KB)

Comments are closed.